Cue Biopharma surges after positive results from mid-stage study for CUE-221
CUE•Phase 2 endpoints met
The company said the phase 2 primary and key secondary endpoints were met.
Shares jump in premarket trading
Cue Biopharma shares soared 28.9% to $47.74 in premarket trading after the company announced positive results from a mid-stage study for CUE-221 in hives treatment.
Recent financial and stock performance
Cue also said earlier this month that its second-quarter revenue more than doubled. Up to the previous day's close, the shares were up more than 300% year to date.
